Literature DB >> 30404418

A New Functional Scale and Ambulatory Functional Classification of Duchenne Muscular Dystrophy: Scale Development and Preliminary Analyses of Reliability and Validity.

Jungyoon Kim1,2, Il-Young Jung1,3, Sang Jun Kim1,4, Joong-Yub Lee5, Sue Kyung Park6,7,8, Hyung-Ik Shin1, Moon Suk Bang1.   

Abstract

OBJECTIVE: To develop a simplified functional scale and classification system to evaluate the functional abilities of patients with Duchenne muscular dystrophy (DMD).
METHODS: A Comprehensive Functional Scale for DMD (CFSD) was developed using the modified Delphi method. The accompanying Ambulatory Functional Classification System for DMD (AFCSD) was developed based on previously published classification systems.
RESULTS: The CFSD consists of 21 items and 78 sub-items, assessing body structure and function, activities, and participation. Inter-rater intraclass correlation coefficient values were above 0.7 for 17 items. The overall limits of agreement between the two examiners ranged from -6.21 to 3.11. The Spearman correlation coefficient between the total score on the AFCSD and the Vignos Functional Scale was 0.833, and 0.714 between the total score of the AFCSD and the Brooke scale. Significant negative correlations existed between the total score for each functional level of the AFCSD and each functional grade of the Vignos and Brooke scales. The total scores of the CFSD varied significantly between the functional grades of the Vignos scale, and specific grades of the Brooke scale. For the AFCSD, total scores of the CFSD varied significantly between the functional levels.
CONCLUSION: We have developed a new scale and the associated classification system, to assess the functional ability of children diagnosed with DMD. Preliminary evaluation of the psychometric properties of the functional scale and classification systems indicate sufficient reliability and concurrent validity.

Entities:  

Keywords:  Ambulatory function; Duchenne muscular dystrophy; Functional scale; Scale development

Year:  2018        PMID: 30404418      PMCID: PMC6246862          DOI: 10.5535/arm.2018.42.5.690

Source DB:  PubMed          Journal:  Ann Rehabil Med        ISSN: 2234-0645


INTRODUCTION

Duchenne muscular dystrophy (DMD) is one of the most commonly inherited genetic muscular disorders. While no curative treatments are currently available, the use of corticosteroids and assisted ventilation delays disease progression, prolongs function, and improves the overall quality of life in patients diagnosed with DMD [1]. With advances in basic and clinical DMD research, novel treatments and interventions are being developed and evaluated, with improvement in functional status serving as the benchmark of effectiveness [2,3]. Yet, clinical scales currently available to assess the functional capacity of patients with DMD present several limitations, which restrict their use as reliable outcome measures in evaluating the effectiveness of clinical interventions and predicting the prognosis. Principal limitations of current functional scales include non-specificity; time required to complete the assessment and poor clinical applicability and relevance; low cultural sensitivity; and poor alignment with interventions currently used for the clinical management of patients with DMD. The Vignos Functional Scale highlights the poor alignment between assessment and current intervention trends, based on an assessment of the effect of knee-ankle-foot orthosis (KAFO) on function; KAFOs are no longer commonly used due to their discomfort and the weak scientific evidence supporting their effectiveness in prolonging functional walking [4,5]. From a perspective of cultural sensitivity, preference for floor-sitting in Asian cultures would further, artificially, reduce the use of KAFOs [6]. Additionally, the widespread use of powered wheelchairs to promote participation is not factored in currently available functional scales [7]. Our study addresses these specific limitations of current functional scales with the development of a simplified functional scale and classification system to evaluate functional abilities in patients with DMD. Our purpose, here, is to describe the methods of development of our Comprehensive Functional Scale for DMD (CFSD) and Ambulatory Functional Classification System for DMD (AFCSD), and to report the results of preliminary testing of inter-rater reliability and concurrent validity.

MATERIALS AND METHODS

All the study procedures were approved by the Institutional Review Board of Seoul National University Hospital (No. 1110-096-382 and 1104-032-357). Informed consent, or assent as appropriate for participants’ age, was obtained for the assessment of reliability and validity. The CFSD was developed using the modified Delphi method [8]. The process consisted of three stages: item generation (stage 1); primary item reduction and scale development (stage 2); and scale evaluation (stage 3). The expert panel was composed of a single pediatric neurologist and six physiatrists. Reliability and validity testing was directed by two statisticians. Authors gathered opinions, provided feedback, and reported conclusions to the expert panel, by e-mail or mail as appropriate, throughout the developmental process and reliability and validity testing. The AFCSD was based on the Gross Motor Function Classification System [9], the Communication Function Classification System [10], and the Manual Ability Classification System [11]. The AFCSD comprises 5 levels, defined as follows: level 1, walking at normal speed and with normal postural alignment ; level 2, walking independently without an assistive device or brace, with evidence of abnormal gait patterns, such as tip-toeing or waddling, and with impaired postural alignment, such as excessive trunk lordosis; level 3, walking across only short distances, using a hand-held mobility device, such as a walker or crutch; level 4, inability to walk and use of a powered wheelchair; and level 5, need for transportation in a manual wheelchair. These 5 classification levels are presented in Fig. 1.
Fig. 1.

Ambulatory functional classification system for Duchenne muscular dystrophy (DMD).

Stage 1: Item generation

The MEDLINE database was searched from January 1965 to June 2009 using the following combinations of terms: (Duchenne muscular dystrophy OR muscular dystrophy) AND (functional evaluation OR functional scale OR activities of daily living). The search identified 305 articles, describing the following key functional scales: the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale [12]; the Barthel Index [13]; the Modified Barthel Index [14]; the Muscular Dystrophy-Specific Functional Rating Scale [15]; the Modified Hammersmith Functional Motor Scale [16]; the Motor Performance Test [17]; the Pediatric Evaluation of Disability Inventory [18]; the Vignos Scale; the Brooke Scale [19]; the Wee Functional Independence Measure [20]; the Gross Motor Function Measure; the Physical Self-Maintenance Scale [21] and the measure of activities of daily living (ADL) and instrumental ADL [21]. A preliminary pool of items was generated following a series of expert panel meetings. Refinement of the preliminary item selection was conducted via a two-step process. In the first step, a closed questionnaire was sent to the members of the expert panel to obtain individual information pertaining to the importance of each item and sub-item (e.g., sitting item and related sub-items for each posture and activity, as described in Supplementary Table S1). The perceived importance of items and sub-items was measured on a Likert scale, ranging from 1 to 5, with the following descriptions provided: very unimportant, unimportant, not important or unimportant, important, and very important. In the second step, the results of the closed-questionnaire were tabulated and summarized as a total score and a mean (SD) score for each item and sub-item, and provided to the expert panel. Each panel member was asked to review the results and to re-score items and sub-items as they deemed applicable.

Stage 2: Primary item reduction and scale development

Following the second round of scoring, ranked items were shared with the expert panel and classified into functional domains. A modified Delphi approach, in conjunction with subsequent meetings of the expert panel, was used to select relevant items and sub-items from the pool of items identified at the end of stage 1.

Stage 3: Preliminary evaluation of the inter-rater reliability and validity of the CFSD and AFCSD

The inter-rater reliability of the CFSD and the AFCSD was evaluated in 48 boys diagnosed with DMD, with a mean age of 5.29±3.51 years. All the items and sub-items were tested by two clinical experts on the same day, a pediatric physiatrist and a pediatric physical therapist. Items derived from established objective measurements, such as the Cobb angle of scoliosis or intelligence quotients, were not included in the evaluation of reliability. Inter-rater reliability of the CFSD and AFCSD, as well as of the Vignos and the Brooke Scales, was evaluated using the intraclass correlation coefficient (ICC), with ICC values >0.7 suggesting acceptable level of reliability. Bland-Altman plots and limits of agreement (mean±1.96 SD) were also calculated. The concurrent validity of the CFSD and AFCSD was evaluated against established functional scales, namely the Vignos and the Brooke Scales. Spearman correlation coefficients were calculated between the total scores of the AFCSD and both the Vignos and the Brooke scales, to provide a global measure of validity. Specific validity of the CFSD was evaluated by comparing total scores on the CFSD to scores for each grade of function on the Vignos and the Brooke scales, and for the 5 levels of the AFCSD. The level of concordance between the grades of the Vignos and Brooke scales and the levels of the AFCSD was assessed using the Kruskal-Wallis test, with the Wilcoxon rank sum test used for post-hoc analyses of differences detected between the scales, with corrections for multiple comparisons according to the false detection rate (FDR) method. All the statistical analyses were performed using the R3.1.0 GUI, with the level of significance set at p<0.05.

RESULTS

The new functional scale for Duchenne muscular dystrophy

A preliminary pool of 174 items, described in Supplementary Table S1, was identified from the structured review of the literature and the series of the expert panel meetings. These items were classified into the following 9 functional domains: mobility, ADL, muscle power, joint contracture, pulmonary function, cardiac function, scoliosis, pain, and cognitive and social function. Highly scored items in each of the 9 domains of function were extracted. In circumstances involving two or more items within a domain sharing similar component activities (e.g., transferring from the bed to a wheelchair and from the wheelchair to a toilet seat), only one item was selected. In addition, when items with a broader meaning yielded scores similar to items measuring specific attributes (e.g., the activity of eating in comparison to individual items of feeding, swallowing, and drinking, which contribute to this activity), the item with the broader meaning was included. The importance of peak cough flow, pulmonary function tests, electrocardiograms, and echocardiograms was acknowledged, and these items were excluded as they are known to be independently associated with the functional prognosis of patients with DMD. Following the methods for item reduction, 21 items and 78 sub-items were retained across the following 7 domains: mobility (8 items), ADL (6 items), contractures (2 items), pulmonary function (2 items), cardiac function (1 item), scoliosis (1 item), and cognition (1 item) (Table 1). A variable grading system was developed to produce a range of qualitatively different levels of functional performance. For example, the item ‘using drugs for heart disease’ was graded on a 2-point scale, 0 and 3 representing negative and affirmative responses, respectively. The total score on the CFSD ranged from a minimum score of 0 to a maximum score of 63, with higher scores representing higher function, and hence, less severe diseaserelated impairment. The full items and scoring systems are described in Table 1.
Table 1.

A comprehensive functional scale for Duchenne muscular dystrophy (CFSD)

Domain in ICFItemScoreItem# in the scale
Body functions andSeverity of knee joint contracture3No limitation15
structures2Mild limitation (ROM >2/3 in normal range)
1Moderate limitation (1/3<Rom<2/3 in normal range
0Severe limitation (ROM <1/3 in normal range)
Severity of hip joint contracture3No limitation16
2Mild limitation (ROM >2/3 in normal range)
1Moderate limitation (1/3<Rom<2/3 in normal range
0Severe limitation (ROM <1/3 in normal range)
Respiratory insufficiency (ventilator assisted)3Not needed17
2During the night time
1During the night and day (<24 hours)
0All day long
Dyspnea3None18
2After activity
1After standing (orthopnea)
0In stable condition
Using drug for heart disease3No19
0Yes
Scoliosis - Cobb angle [24-26]3None (Cobb's angle <20°)20
2Mild (20<cobb's angle<30°
1Moderate (Cobb's angle <50°)
0Severe (Cobb's angle ≥50°) or post-operative state
Intellectual disability (ID; WISC-III or KEDI-WISC) [27-29]3None21
2Mild ID (50–69)
1Moderate ID (35–49)
0Severe ID (<35)
ActivityStair climbing3Climbs stairs without assistance1
2Climbs stairs with aid of railing
1Restrictively climbs stair with assistance
0Cannot climb stairs
Running3Runs with normal speed2
2Slowly runs without assistance (other person)
1Slowly runs with assistance (other person)
0Cannot run
Walking3Walks without assistance and rises from chair3
2Slowly walks unassisted but cannot rise from chair
1Slowly walks with assistance
0Unable to walk even with assistance
Standing3Stand from a floor5
2Stand from a chair
1Only stand with assistance
0Cannot stand
Sitting3Sit from lying without assistance6
2Sit from lying with assistance (device or person)
1Only maintain sitting position
0Cannot maintain sitting position
Transferring from bed to chair3Transfer from bed to chair without assistance7
2Transfer with minimal assistance
1Transfer with moderate assistance
0Totally need assistance for transfer
Rolling (changing body position in bed)3Fully roll in bed without assistance8
2Roll in bed with minimal assistance
1Roll in bed with moderate assistance
0Cannot roll
Eating3Independent9
2With minimal assistance
1With moderate assistance
0Totally dependently
Grooming3Independent10
2With minimal assistance
1With moderate assistance
0Totally dependent
Toileting3Independent11
2With minimal assistance
1With moderate assistance
0Totally dependent
Bathing3Independent12
2With minimal assistance
1With moderate assistance
0Totally dependent
Dressing3Independent13
2With minimal assistance
1With moderate assistance
0Totally dependent
ParticipationIndoor mobility (school attendance, social interaction)3Has active social interaction with school attendance4
2Has active social interaction without school attendance
1Has simple social interaction without school attendance
0Has no social interaction
Using personal computer3Using PC without assistive devices14
2Using PC with simple assistive devices
1Using PC with complex assistive devices
0Cannot use PC
Total scoreMin=0 Max=63

ICF, International Classification of Functioning, Disability, and Health; ROM, range of motion; WISC-III, Wechsler Intelligence Scale Children 3rd edition; KEDI-WISC, Korean Wechsler Intelligence Scale for Children-Revised.

Reliability and validity

Reliability

The ICCs between two examiners are reported in Table 2. Two out of the 48 subjects were excluded from the analysis due to missing discrete item scores. Interrater ICC values were below the cutoff of 0.7, set a priori, for the following four CFSD items: indoor activities (ICC=0.680), personal computer utilization (ICC=0.638), ventilator assist (ICC=0.662), and presence of dyspnea (ICC=0.453). Evaluation of the limits of agreement of the total AFCSD score between the two examiners indicated disagreement for a discrete outlier within one level (Fig. 2). With this exception, the overall limits of agreements ranged between -6.21 and 3.11 (Fig. 3A). These limits of agreement narrowed to a range of -5.54 to 3.19 when the items scoring ICC values <0.7 were removed from the calculation (Fig. 3B).
Table 2.

ICC for each item between two independent examiners

ItemICCp-value95% CI
1Stair0.951<0.0010.912–0.972
2Running0.874<0.0010.785–0.928
3Walking0.979<0.0010.963–0.988
4Indoor0.680[*]<0.0010.490–0.808
5Standing0.961<0.0010.932–0.978
6Sitting0.912<0.0010.846–0.950
7Transfer0.994<0.0010.989–0.997
8Rolling0.872<0.0010.775–0.928
9Eating0.727<0.0010.560–0.837
10Grooming0.730<0.0010.565–0.839
11Toileting0.829<0.0010.713–0.900
12Bathing0.701<0.0010.482–0.830
13Dressing0.918<0.0010.851–0.955
14Using personal computers0.638[*]<0.0010.434–0.780
15Knee contracture0.909<0.0010.843–0.948
16Hip contracture0.718<0.0010.546–0.832
17Ventilator0.662[*]<0.0010.469–0.795
18Dyspnea0.453[*]<0.0010.193–0.652
19Drug for heart0.880<0.0010.796–0.931
AFCSD0.967<0.0010.940–0.981

ICC, intra-class correlation coefficient; AFCSD, ambulatory functional classification for Duchenne muscular dystrophy.

ICC<0.700.

Fig. 2.

Bland-Altman plot for agreements between examiners 1 and 2 in the ambulatory functional classification system for Duchenne muscular dystrophy (AFCSD). Blue horizontal lines show a 97.5% limit, median, and 2.5% limit of the agreements.

Fig. 3.

Bland-Altman plot for agreements between examiners 1 and 2 in the total score of the new functional scale. (A) Total score ranging from item 1 to 19; (B) items with acceptable (>0.7) intraclass correlation coefficients. Blue horizontal lines show a 97.5% limit, median, and 2.5% limit of the agreements.

Validity

The Spearman correlation coefficient between the total score on the CFSD and on the Vignos scale was 0.833 (p<0.001), and 0.714 (p<0.001) between the total score of the CFSD and the Brooke Scale. The following significant correlations were calculated between the total CFSD score and the Vignos and Brooke scales or AFCSD: -0.818, -0.645, and -0.686 for the Vignos Scale, the Brooke Scale, and the AFCSD, respectively (p<0.001 for all pairs). The mean (SD) scores for the CFSD score and each grade of the Vignos and Brooke scales, and the levels of the AFCSD are presented in Table 3. As shown in Fig. 4A, the total scores varied significantly between the following functional grades of the Vignos scale: 1 and 2; 1 and 4; 1 and 9; 2 and 9; 3 and 9; and 4 and 9. For the Brooke scale, the total scores were distinct for functional grades 2 and 3 (Fig. 4B). For the AFCSD, the total scores varied significantly between the functional levels 1 and 5 and 2 and 5 (Fig. 5).
Table 3.

Summary of the total score in each level and grade of the AFCSD, the Vignos and the Brooke Scales

Number of the subjectsTotal score of new functional scale
AFCSD
 Level 11753 (42–57)
 Level 21751 (33–56)
 Level 3240.5 (34–47)
 Level 4223 (17–29)
 Level 5821.5 (17–27)
Vignos scale
 1954 (51–57)
 21951 (43–55)
 3352 (49–53)
 4346 (42–47)
 5233.5 (33–34)
 60NA
 70NA
 80NA
 91021.5 (17–29)
 100NA
Brooke scale
 13351 (17–57)
 2631.5 (21–52)
 3425.5 (21–33)
 4122[a)]
 5217[b)]
 60NA

Values are presented as median (min–max).

AFCSD, ambulatory functional classification for Duchenne muscular dystrophy; NA, not applicable.

Standard deviation was not applicable because only one subject scored Brooke scale 4.

Two subjects with Brooke scale 5 scored the same value on the new functional scale.

Fig. 4.

Total scores of the comprehensive functional scale under each grade: (A) Vignos scale, and (B) Brooke scale. In the Vignos scale, scores varied significantly between grades 1–2, 1–4, 1–9, 2–9, 3–9, and 4–9. In the Brooke scale, scores between grade 2 and 3 differ from each other. Lower and upper margins of the box present the lower quartile (Q1) and the upper quartile (Q3) of the total score. The band inside the box indicates median, and the whiskers range from Q1+1.5 interquartile range (IQR) to Q3+IQR. Hollow circles represent outliers. Horizontal lines above the box graph depict significant differences in the Wilcoxon rank sum test (adjusted p<0.05).

Fig. 5.

Total scores in each level of the ambulatory functional classification system for Duchenne muscular dystrophy (AFCSD). Significant differences in the total score were found between 1–5, and 2–5. Lower and upper margins of the box present the lower quartile (Q1) and the upper quartile (Q3) of the total score. The band inside the box indicates median, and the whiskers range from Q1+1.5 interquartile range (IQR) to Q3+IQR. Hollow circles show outliers. Horizontal lines above the box graph depict significant differences in the Wilcoxon rank sum test (adjusted p<0.05).

DISCUSSION

In this study, we describe the development and preliminary testing of inter-rater reliability and concurrent validity of a new functional scale and functional classification system for children diagnosed with DMD, the CFSD and AFCSD, respectively. These two new clinical assessments consist of items deemed essential to the function of patients with DMD based on the results of our longitudinal study [22]. By incorporating items from all three domains of the International Classification of Functioning, Disability, and Health (ICF), including body functions and structures, activities, and participation, our novel clinical tools provide a comprehensive functional assessment of patients with DMD. Furthermore, we have improved the relevance of our assessment compared with currently available clinical tools, by including items reflective of technology utilization, such as personal computers and powered-wheelchairs. Therefore, we propose that our functional scale and classification system provide meaningful outcomes in evaluating the effectiveness of novel treatments and interventions in an effort to improve the outcomes of patients with DMD, as well as to more reliably predict clinical prognosis. The CFSD and AFCSD, therefore, represent valuable tools to include in the large number of clinical trials investigating patients with DMD.

A new functional scale for Duchenne muscular dystrophy

Novel items of the CFSD evaluating indoor activities, personal computer utilization, ventilator assistance, and presence of dyspnea scored ICC values <0.7. A review of these items indicates that the low reliability of the scores may reflect the vagueness of terms used, such as ‘active’ and ‘simple’ social interactions, which may be interpreted differently by different examiners. Language subtleties may influence the reliability scores. As an example, while mechanical ventilators and mechanical insufflators and exsufflators have adistinct meaning in English, a common wording is used in Korean (‘hoheup-bojogi’ vs. ‘kichimbojogi’). The low reliability scores for items on dyspnea may specifically reflect the existing vagueness surrounding the description of respiratory symptoms in children with DMD. For example, dyspnea associated with ventilation insufficiency rather than oxygenation insufficiency tends to be poorly differentiated until symptoms become severe and require intervention. The total CFSD scores correlated strongly with the total scores on the Vignos and the Brooke scales. These high correlation coefficient scores might be useful to differentiate mild functional impairments, as the scores varied significantly from those for grades 1 and 2 on the Vignos scale (Fig. 4A). This sensitivity of the CFSD and AFCSD in differentiating grades of function in children in the early (mild) phases of DMD progression might be important in measuring changes after medical interventions and rehabilitation in the early stages of DMD. However, we must also consider the benefit of less granular classification grades; as an example, grade 2 on the Brooke scale includes a broad range of total scores (Fig. 4B), which might reflect diverse compensatory strategies that children with DMD adopt to accomplish functional goals during the early stages of the disease.

Ambulatory functional classification system for Duchenne muscular dystrophy

The high Spearman correlation coefficients between the AFCSD and the Vignos and the Brooke scales indicate concurrent validity of the AFCSD. However, as 34 of the 46 participants in this study (73.9%) were classified under level 1 or 2 on the AFCSD, with only a few children classified under levels 3 and 4, the total CFSD scores varied significantly only between levels 1 and 5 and levels 2 and 5. As the scores were not normally distributed, the mean (SD) values of total scores within each classification level could not be calculated.

Limitations

The study group manifested a skewed distribution of disease severity, with the majority of children in the mild phase of the disease: 28/46 (60.9%) and 33/46 (71.7%) classified under grades 1 and 2 of the Vignos and Brooke scales, respectively, whereas 34/46 (73.9%) were classified under levels 1 and 2 of the AFCSD. Validation of the CFSD and AFCSD for children at more progressive stages of disease severity requires large-scale clinical trials, with a normal distribution of participants across all stages of DMD disease severity. Each stage of the AFCSD represents the functional levels of children with DMD. However, it does not contain age-specific or developmental stage-specific information. Further validation and modification of each stage requires testing in a larger population of children with DMD. The intra-rater reliability of each item of the CFSD was not tested in this study as the participants and their legal guardians refused to undergo prolonged evaluation. Intra-rater reliability of each item should be further investigated in a subsequent study. The validity of the CFSD also needs to be tested further using comprehensive evaluation tools such as the Gross Motor Functional Measure, Modified Barthel Index, Pediatric Evaluation of Disability Inventory, and Functional Independence Measure for Children (WeeFIM). Relatively new functional scales, such as North Star Ambulatory Assessment [23] or motor function measurement scale were not included in the item generation because they were not widely used at the time this study was conducted.

Conclusions

We have developed a new scale, and associated classification system, to assess function in patients diagnosed with DMD. Preliminary evaluation of the psychometric properties of the functional scale and classification system indicate sufficient reliability and concurrent validity to include the CFSD and AFCSD in large-scale clinical trials.
  27 in total

1.  Assessment of everyday functioning in young children with disabilities: an ICF-based analysis of concepts and content of the Pediatric Evaluation of Disability Inventory (PEDI).

Authors:  Sigrid Østensjø; Wenche Bjorbaekmo; Eva Brogren Carlberg; Nina K Vøllestad
Journal:  Disabil Rehabil       Date:  2006-04-30       Impact factor: 3.033

2.  Development and reliability of a system to classify gross motor function in children with cerebral palsy.

Authors:  R Palisano; P Rosenbaum; S Walter; D Russell; E Wood; B Galuppi
Journal:  Dev Med Child Neurol       Date:  1997-04       Impact factor: 5.449

3.  The Knud Jansen lecture. Technological choices in prosthetics and orthotics for developing countries.

Authors:  P K Sethi
Journal:  Prosthet Orthot Int       Date:  1989-12       Impact factor: 1.895

4.  Probable future funding priorities in maternal and child health: a modified Delphi National Survey.

Authors:  G P Loos; R G Smith; C Roseman
Journal:  J Health Polit Policy Law       Date:  1985       Impact factor: 2.265

5.  Clinical trial in Duchenne dystrophy. I. The design of the protocol.

Authors:  M H Brooke; R C Griggs; J R Mendell; G M Fenichel; J B Shumate; R J Pellegrino
Journal:  Muscle Nerve       Date:  1981 May-Jun       Impact factor: 3.217

6.  A new motor performance test in a prospective study on children with suspected myopathy.

Authors:  Willeke A van den Beld; Gitty A C van der Sanden; Ton Feuth; Anjo J W M Janssen; Rob C A Sengers; André L M Verbeek; Fons J M Gabreëls
Journal:  Dev Med Child Neurol       Date:  2006-09       Impact factor: 5.449

Review 7.  The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature.

Authors:  J P Bakker; I J de Groot; H Beckerman; B A de Jong; G J Lankhorst
Journal:  Clin Rehabil       Date:  2000-08       Impact factor: 3.477

Review 8.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

9.  Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.

Authors:  Jane T Seto; Niclas E Bengtsson; Jeffrey S Chamberlain
Journal:  Curr Pediatr Rep       Date:  2014-06-01

10.  Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.

Authors:  Thomas Voit; Haluk Topaloglu; Volker Straub; Francesco Muntoni; Nicolas Deconinck; Giles Campion; Sjef J De Kimpe; Michelle Eagle; Michela Guglieri; Steve Hood; Lia Liefaard; Afrodite Lourbakos; Allison Morgan; Joanna Nakielny; Naashika Quarcoo; Valeria Ricotti; Katie Rolfe; Laurent Servais; Claire Wardell; Rosamund Wilson; Padraig Wright; John E Kraus
Journal:  Lancet Neurol       Date:  2014-09-07       Impact factor: 44.182

View more
  3 in total

1.  Revisiting the pathogenic role of insulin resistance in Duchenne muscular dystrophy cardiomyopathy subphenotypes.

Authors:  Antoine Fakhry AbdelMassih; Reem Esmail; Hanan Zekri; Ahmed Kharabish; Khaled ElKhashab; Rahma Menshawey; Habiba-Allah Ismail; Peter Afdal; Erini Farid; Omneya Affifi
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-05-18

2.  Efficacy of two intervention approaches on functional walking capacity and balance in children with Duchene muscular dystrophy.

Authors:  Abd El Aziz A Sherief; Heba Gaber Abd ElAziz; Mostafa S Ali
Journal:  J Musculoskelet Neuronal Interact       Date:  2021-09-01       Impact factor: 2.041

3.  The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy.

Authors:  Sarah E Henson; Sean M Lang; Philip R Khoury; Cuixia Tian; Meilan M Rutter; Elaine M Urbina; Thomas D Ryan; Michael D Taylor; Tarek Alsaied
Journal:  J Am Heart Assoc       Date:  2021-09-25       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.